Eupraxia Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Eupraxia Pharmaceuticals has a total shareholder equity of $892.3K and total debt of $10.4M, which brings its debt-to-equity ratio to 1165.3%. Its total assets and total liabilities are $20.3M and $19.4M respectively.
Key information
1,165.3%
Debt to equity ratio
US$10.40m
Debt
Interest coverage ratio | n/a |
Cash | US$19.34m |
Equity | US$892.33k |
Total liabilities | US$19.37m |
Total assets | US$20.27m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: EPRX's short term assets ($19.8M) exceed its short term liabilities ($19.4M).
Long Term Liabilities: EPRX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: EPRX has more cash than its total debt.
Reducing Debt: EPRX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EPRX has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: EPRX is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital.